CTOs on the Move


 
Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. We started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. We achieve our goals by: • investing in research and development ...
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.acorda.com
  • 420 Saw Mill River Road
    Ardsley, NY USA 10502
  • Phone: 800.367.5109

Executives

Name Title Contact Details

Similar Companies

Mo Bio Labs

Mo Bio Labs is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Appia Bio

Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Stem Centrx

Stem Centrx is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.

CHUL Research Center

CHUL Research Center is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.